{"uid":"cap_fzKXy3jKAaqndmZ0C0ChV","slug":"lightning-ai-visibility-data-pharma-moderate-to-severe-atopic-65ef8567","name":"Lightning AI Visibility Data – Pharma – Moderate-to-Severe Atopic Dermatitis – Argentina 2026","description":"AI Visibility - Pharma - Moderate-to-Severe Atopic Dermatitis - Argentina 2026 (Visibilidad IA - Farma - Dermatitis atopica moderada a severa - Argentina 2026). Full study in one call: question-universe design, 534 raw AI answers (6 models), 30 analysis tables with Lightning metrics, 45 findings with evidence. Spanish-language data from Argentina, run 2026-07-06. By Lightning (lightningeo.com).","url":"https://api.lightningeo.com/estudio/dermatitis-atopica-2026?utm_source=zero.xyz","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET"],"type":"string"},"queryParams":{"type":"object","properties":{"vista":{"enum":["completo","resumen"],"type":"string","description":"completo = whole study (default); resumen = design + findings + metrics + analysis index (lighter, same price)"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}},"responseSchema":null,"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.99","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.99/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.99","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.99","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_jG6fElSXtoaIa0o9AAVKE","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.99","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns a full AI visibility study on moderate-to-severe atopic dermatitis pharma brands in Argentina, including 534 raw AI answers across 6 models, 30 analysis tables, and 45 evidence-backed findings in Spanish.","exampleAgentPrompt":"Pull the full Lightning AI visibility study on moderate-to-severe atopic dermatitis pharma brands in Argentina 2026 — I want all 534 AI answers, the 30 analysis tables, and the 45 findings with evidence.","exampleUseCases":[{"title":"Competitive pharma brand benchmarking","prompt":"Get me the complete Lightning AI visibility study on moderate-to-severe atopic dermatitis in Argentina — I need to see how all the competing pharma brands rank across the 6 AI models and what the analysis tables say about brand presence."},{"title":"Regulatory and market entry research","prompt":"I'm evaluating the Argentine atopic dermatitis market for 2026 — can you pull the Lightning AI visibility study and give me the summary view with the key findings and metrics, not the full raw answers?"},{"title":"AI content strategy for dermatology brand","prompt":"Our brand is in the moderate-to-severe atopic dermatitis space in Argentina — pull the full Lightning AI visibility study for 2026 so I can see what the 45 findings say and where we appear across AI model responses."}],"resultDescription":"Returns a structured JSON study containing: the question-universe design used to probe AI models, 534 raw AI answers collected from 6 different AI models, 30 analysis tables with Lightning's proprietary AI visibility metrics, and 45 findings with supporting evidence — all in Spanish, scoped to Argentina's moderate-to-severe atopic dermatitis pharmaceutical market as of July 2026. A lighter 'resumen' view returns the design, findings, metrics, and analysis index without the full raw answers.","failureModes":["Invalid or unsupported vista parameter value returns a validation error","Network or payment authorization failure via x402 protocol returns 402 Payment Required","Study not found or URL path mismatch returns 404","Server-side data retrieval timeout returns 503 or 504"],"whenToPreferThis":"Choose this endpoint when you need pre-computed, multi-model AI visibility intelligence specifically for moderate-to-severe atopic dermatitis pharmaceuticals in Argentina for 2026, delivered as a single structured call with raw answers, analysis tables, and findings. Prefer this over general web search or manual AI querying when you need standardized metrics across 6 AI models with evidence-backed findings in Spanish.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-10-17T12:38:27.371Z","isFirstParty":false,"canonicalSlug":"lightning-ai-visibility-data-pharma-moderate-to-severe-atopic-65ef8567"}